Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Compass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at the highest dose levels and no dose-limiting toxicities observed.